Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Therapeutic potential of mesenchymal stem cells to attenuate immune cell tolerance in a late stage model of sepsis

Declan Byrnes, Claire Masterson, Shahd Horie, Jack Brady, Hector Gonzalez, Sean Mccarthy, Daniel O'Toole, John Laffey
European Respiratory Journal 2020 56: 2579; DOI: 10.1183/13993003.congress-2020.2579
Declan Byrnes
1Lung Biology Group, National University of Ireland Galway, Galway, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: declanbyrnes@hotmail.com
Claire Masterson
1Lung Biology Group, National University of Ireland Galway, Galway, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shahd Horie
1Lung Biology Group, National University of Ireland Galway, Galway, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jack Brady
1Lung Biology Group, National University of Ireland Galway, Galway, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hector Gonzalez
1Lung Biology Group, National University of Ireland Galway, Galway, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean Mccarthy
1Lung Biology Group, National University of Ireland Galway, Galway, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel O'Toole
1Lung Biology Group, National University of Ireland Galway, Galway, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Laffey
2Anaesthesia and Intensive Care Medicine, Galway University Hospitals, Galway, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Introduction: Patients who survive early stage sepsis may progress to late stage sepsis which is characterised by immunosuppression believed to be due, in part, to immune cell paralysis. We have previously shown that Mesenchymal Stem Cells (MSCs) are effective in preclinical models of early stage sepsis (Devaney et al., 2015) and to restore macrophage function in early clinical sepsis. We sought to develop in vivo and in vitro late stage sepsis models to assess if MSCs could restore immune cell homeostasis in this setting.

Methods: We established an in vivo model of pulmonary sepsis by intratracheal administration of K.pneumoniae to Sprague-Dawley rats. MSCs were administered at day two and immune cell and cytokine secretion profiles in the Bronchoalveolar Lavage (BAL) and blood were analysed at day five. An in vitro endotoxin tolerance model was then established using immune cell lines and primary macrophages from blood and BAL exposed to repeated high levels of endotoxin.

Results: MSCs improve paralysed immune cell responsiveness to an endotoxin stimulus ex vivo as demonstrated by a restoration of cytokine secretion in cells isolated from treated animal models (Figure 1).

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Conclusions: MSCs have the potential to reverse late sepsis induced immune cell dysfunction caused by prolonged exposure to bacterial endotoxin ex vivo.

  • Animal models
  • Treatments
  • Sepsis

Footnotes

Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2579.

This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2020
Previous
Back to top
Vol 56 Issue suppl 64 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Therapeutic potential of mesenchymal stem cells to attenuate immune cell tolerance in a late stage model of sepsis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Therapeutic potential of mesenchymal stem cells to attenuate immune cell tolerance in a late stage model of sepsis
Declan Byrnes, Claire Masterson, Shahd Horie, Jack Brady, Hector Gonzalez, Sean Mccarthy, Daniel O'Toole, John Laffey
European Respiratory Journal Sep 2020, 56 (suppl 64) 2579; DOI: 10.1183/13993003.congress-2020.2579

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Therapeutic potential of mesenchymal stem cells to attenuate immune cell tolerance in a late stage model of sepsis
Declan Byrnes, Claire Masterson, Shahd Horie, Jack Brady, Hector Gonzalez, Sean Mccarthy, Daniel O'Toole, John Laffey
European Respiratory Journal Sep 2020, 56 (suppl 64) 2579; DOI: 10.1183/13993003.congress-2020.2579
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • The matrix-fibroblast interplay contributes to HIF-1 alpha pathway activation: a possible therapeutic target in idiopathic pulmonary fibrosis (IPF)
  • High-plex immunofluorescence single cell analysis of fibrotic murine lung on tissue microarrays
  • Divergent effects of MIF on lung alveolar repair
Show more Mechanisms of lung injury and repair

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society